论文部分内容阅读
作者比较了一个高发区(香港),一个中等发病区(突尼斯)和二个低发区(北美和法国)的鼻咽癌病人和对照组的抗EB病毒相关抗原的抗体滴度,以了解抗体滴度与发病率的关系,并希望找出那一种抗EB病毒抗体能最有效地区分鼻咽癌患者和对照组,对照癌组包括:头颈部肿瘤、肠胃道肿瘤、肉瘤、皮肤癌、乳癌、肺癌、脑瘤、泌尿生殖系肿瘤及原发灶不明的转移性腺癌等。比较研究尽可能考虑(年龄、性别、种族和居住国家等)配对条件。测定的抗体包括:抗病毒壳抗原(VCA)、抗早期抗
The authors compared antibody titers against EBV associated antigens in a high-risk area (Hong Kong), a middle-incidence area (Tunisia), and two low-risk areas (North America and France) in patients with nasopharyngeal carcinoma and controls. The relationship between titer and incidence, and hope to find out which anti-EB virus antibody can most effectively distinguish patients with nasopharyngeal carcinoma and control group, the control group includes: head and neck tumors, gastrointestinal tumors, sarcoma, skin cancer Breast cancer, lung cancer, brain tumors, urogenital tumors, and metastatic adenocarcinoma of unknown primary tumor. Comparative studies consider as many as possible (age, sex, race, country of residence, etc.) matching conditions. The antibodies tested include: anti-viral shell antigen (VCA), anti-early resistance